Get the Stockscreener App
4.44
6.22%
0.26
Cingulate Inc stock is traded at $4.44, with a volume of 214.51K.
It is up +6.22% in the last 24 hours and up +16.84% over the past month.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
See More
Previous Close:
$4.18
Open:
$4.18
24h Volume:
214.51K
Relative Volume:
1.23
Market Cap:
$30.00M
Revenue:
-
Net Income/Loss:
$-21.21M
P/E Ratio:
-0.1362
EPS:
-32.6
Net Cash Flow:
$-16.86M
1W Performance:
+11.28%
1M Performance:
+16.84%
6M Performance:
+0.91%
1Y Performance:
+5.21%
1-Day Range:
$4.1501
$4.48
1-Week Range:
$3.75
$4.48
52-Week Range:
$3.20
$6.01
Cingulate Inc Stock (CING) Company Profile
Name
Cingulate Inc
Sector
Industry
Phone
(913) 942-2300
Address
1901 W. 47TH PLACE, KANSAS CITY
Compare CING with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
4.44 | 28.24M | 0 | -21.21M | -16.86M | -32.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | ROTH MKM | Buy |
| Dec-22-23 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Stock (CING) Latest News
Cingulate Inc Equity Warrant Stock Analysis and ForecastEarnings Season Recap & Outstanding Capital Returns - earlytimes.in
Cingulate presents Phase 3 results for CTx-1301, met primary endpoint - MSN
Ascendiant Capital Maintains Cingulate (CING) Buy Recommendation - Nasdaq
Cingulate reports Q3 net loss ($7.3M) vs ($4.1M) last year - MSN
Cingulate Inc. Reports Q3 2025 Financial Results - MSN
Can Cingulate Inc. Equity Warrant stock deliver surprise earnings beatMarket Growth Report & Stepwise Trade Signal Implementation - Newser
Will Cingulate Inc. stock attract more institutional investorsPortfolio Gains Summary & Fast Exit Strategy with Risk Control - Newser
How strong is Cingulate Inc. stock balance sheetCEO Change & Accurate Intraday Trade Tips - Newser
Cingulate Inc. (NASDAQ:CING) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
How Dhanvantri Jeevan Rekha Limiteds Balance Sheet Supports LongTerm GrowthPrice Support Zones & Superior Wealth Building - earlytimes.in
Cingulate Inc Stock Analysis and ForecastEnergy Sector Updates & Chat With Other Investors on Daily Signals - earlytimes.in
Will Cingulate Inc. stock maintain dividend yieldEarnings Recap Summary & Precise Buy Zone Tips - moha.gov.vn
Will Cingulate Inc. stock return to pre crisis levelsPortfolio Return Summary & Consistent Growth Equity Picks - BỘ NỘI VỤ
Sentiment Recap: Will Cingulate Inc. stock gain from lower inflation2025 Major Catalysts & High Accuracy Swing Entry Alerts - moha.gov.vn
Who’s Hired? Alvotech Promotes McClellan To COO - Citeline News & Insights
Is There NearTerm Timing Risk on India Glycols Limited StockPrice Momentum Alerts & Big Gains Low Investment - earlytimes.in
Press Release: Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update - 富途牛牛
Is Cingulate Inc. Equity Warrant stock dividend yield sustainable - newser.com
Zacks Small Cap Lowers Earnings Estimates for Cingulate - Defense World
Cingulate price target lowered to $16 from $17 at Roth Capital - Yahoo Finance
Why Cingulate Inc. Equity Warrant stock remains on buy listsPortfolio Return Report & Safe Entry Zone Identification - newser.com
Will breakout in Cingulate Inc. Equity Warrant lead to full recoveryJuly 2025 Trends & Technical Analysis for Trade Confirmation - newser.com
What data driven models say about Cingulate Inc.’s futureMarket Sentiment Report & Short-Term High Return Strategies - newser.com
How Cingulate Inc. stock performs in high volatility markets2025 EndofYear Setup & Safe Entry Zone Tips - newser.com
Signal strength of Cingulate Inc. stock in tech scannersWeekly Trend Recap & Real-Time Stock Entry Alerts - newser.com
Will Cingulate Inc. Equity Warrant stock recover faster than marketJuly 2025 Patterns & Capital Efficiency Focused Ideas - newser.com
Published on: 2025-11-19 18:10:29 - newser.com
Can Cingulate Inc. Equity Warrant stock deliver consistent earnings growth - newser.com
Strategies to average down on Cingulate Inc. Equity Warrant2025 Fundamental Recap & Safe Swing Trade Setup Alerts - newser.com
Is Cingulate Inc. Equity Warrant stock in correction or buying zoneJuly 2025 Levels & AI Based Buy and Sell Signals - newser.com
Roth Capital Maintains Cingulate (CING) Buy Recommendation - Nasdaq
Is Cingulate Inc. stock ready for a breakoutJuly 2025 Recap & Community Verified Trade Signals - newser.com
Published on: 2025-11-19 05:53:07 - newser.com
Can Cingulate Inc. stock sustain revenue growthTrade Entry Report & Safe Entry Trade Signal Reports - newser.com
Cingulate Advances ADHD Treatment CTx-1301 Toward Potential 2026 FDA Approval - citybuzz
Does Cingulate Inc. fit your quant trading modelQuarterly Portfolio Report & Target Return Focused Picks - newser.com
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25 - TradingView
Cingulate (NASDAQ: CING) Gains FDA Acceptance of CTx-1301 NDA, Eyes ADHD Launch - Stock Titan
Cingulate Inc Stock (CING) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):